Working hoursMon-Fri 10-20Call us+ 1 555 2345 765
October 28, 2025
Braftovi-Encorafenib-1280x800.jpg

Braftovi or encorafenib is a prescription medication used to treat certain cancers that have spread (metastasized), cannot be removed with surgery, and have specific mutations in the BRAF gene. It is used in  to treat (a) Melanoma and Non-Small Cell Lung Cancer (NSCLC): In combination with Mektovi (binimetinib), encorafenib is used to treat adults with melanoma or NSCLC that has a BRAF mutation. (b) Colorectal Cancer (CRC): In combination with cetuximab and mFOLFOX6 (a chemotherapy regimen including fluorouracil, leucovorin, and oxaliplatin) to treat colorectal cancer.

The approval for this combination was based on response of the tumour and its duration. Ongoing studies are evaluating the clinical benefit of this regimen.
Encorafenib may also be used in combination with cetuximab alone for adults with colorectal cancer who have previously received treatment.
Encorafenib is advised against for the treatment of people whose melanoma, colorectal cancer, or NSCLC has wild-type BRAF (no BRAF mutation), due to insufficient studies. Your healthcare provider will perform a test to confirm if encorafenib or the combination with binimetinib is appropriate for your condition.

Encorafenib is a BRAF kinase inhibitor targeting mutated BRAF – BRAF V600E, wild-type BRAF, and CRAF, inhibiting tumor growth via the suppression of RAF/MEK/ERK pathway. It also binds other kinases at clinically relevant levels. In combination with binimetinib or cetuximab, it showed better anti-tumor effects and delayed resistance in BRAF-mutant models. Resistance in BRAF-mutant CRC due to EGFR activation can be overcome with EGFR-targeted combination therapy.

New primary malignancies, hemorrhage, uveitis and QT prolongation are the common side effects of encorafenib treatment. Breastfeeding is not recommended during treatment and for 2 weeks after. Encorafenib may impact and impair male fertility and reduce any effectiveness of hormonal contraceptives. Therefore, non-hormonal contraception is advised. Effective contraception used during and for 2 weeks after therapy.

In clinical trials, no significant effect of the product’s safety or effectiveness were seen in elderly patients. However, it is not approved for pediatric use. No dose adjustment is needed for mild to moderate renal or hepatic impairment, and use in severe impairment lacks dosing recommendations.

Pricing and availability: 

Encorafenib (Braftovi) is a targeted therapy designed for adults with melanoma, NSCLC, and colorectal cancer with a BRAF mutation that have spread or cannot be surgically removed. It aids in improving tumor response and the duration of benefit. When used in combination with binimetinib or cetuximab-based regimens, it offers a powerful, personalized treatment. It is not suitable for cancers without the BRAF mutation.

However, encorafenib is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for encorafenib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. 

The price of encorafenib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy encorafenib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access

As encorafenib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like encorafenib in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Braftovi or encorafenib is supplied as 75 mg capsules available in cartons containing two bottles of 90 capsules each and cartons containing two bottles of 60 capsules each. 

Import process:

  1. Request submission for your medicine
    Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
  2. Submission of an application (Form 12A)
    Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
  3. Verification of documents
    We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
  4. Permission to import
    Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
  5. Sourcing the medicine
    Our sourcing team connects with authorized global suppliers to find the best encorafenib price in India, thus making it convenient to easily import encorafenib in India, and ensure authenticity before finalizing the offer.
  6. Delivery of the medicine
    After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require: 

To enable the product’s import to India, patients need to provide:

  1. A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
  2. Recent medical history and test reports (preferably from the last three months), including those confirming disease. 
  3. Government-issued ID proof and proof of residence of the patient.
  4. Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Braftovi from the USA, Canada, Europe, or Australia, etc. 
With these steps, patients can import encorafenib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

Accessing Encorafenib (Braftovi) in India can be made seamless and compliant through the Named Patient Supply (NPS) Program. With proper guidance, patients can obtain this essential therapy safely and legally under the supervision of qualified healthcare professionals.

At 24/7 QualityMeds, we assist patients and caregivers through every stage—from documentation and regulatory approvals to sourcing from verified international suppliers. Our focus is on ensuring genuine medicines, transparent pricing, and reliable delivery across India. For the most updated details on Encorafenib pricing, availability, and import assistance in India, please contact our expert support team.


October 25, 2025
Tucatinib-Blog-25-10-2025-1280x800.jpg

Tukysa is a HER2-directed tyrosine kinase inhibitor approved in combination therapy that has demonstrated a significant overall survival benefit in patients with HER2-positive metastatic breast cancer—including those with brain metastases. Its ability to cross the blood-brain barrier and maintain efficacy makes it a critical advancement in treatment of HER2+ disease. Its favorable tolerability profile, and ability to be used post multiple HER2-targeted therapies make it a valuable option in the treatment landscape for HER2-positive metastatic breast cancer.

This product manufactured by Seagen (Seattle Genetics) is a HER2-directed kinase inhibitor, meaning it blocks HER2 and HER3 phosphorylation in vitro, inhibiting downstream MAPK and AKT signaling, and reducing cell proliferation. It has shown anti-tumor activity in HER2-expressing cells. In vivo, tucatinib inhibited HER2-positive tumor growth. When combined with trastuzumab, tucatinib demonstrated enhanced anti-tumor effects in both in vitro and in vivo models compared to either agent alone.

Recommended dosage is 300 mg, orally, twice daily with or without food; and for patients with severe hepatic impairment is 200 mg orally twice daily. 

Some of the clinically significant adverse reactions include diarrhea, embryo fetal toxicity  and hepatotoxicity. 

Pricing and availability: 

Tucatinib (Tukysa) is prescribed for patients with HER2- positive metastatic breast cancer. However, tucatinib is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for tucatinib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. 

The price of tucatinib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy tucatinib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access

As tucatinib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like tucatinib in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Tukysa or tucatinib is supplied as 50 mg or 150 mg tablets with 60 counts in each of 75 cc bottles or 150 mg tablets as 120 counts in each of 150 cc bottles. 

Import process:

  1. Request submission for your medicine
    Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
  2. Submission of an application (Form 12A)
    Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
  3. Verification of documents
    We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
  4. Permission to import
    Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
  5. Sourcing the medicine
    Our sourcing team connects with authorized global suppliers to find the best anakinra price in India, thus making it convenient to easily import tucatinib in India, and ensure authenticity before finalizing the offer.
  6. Delivery of the medicine
    After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require: 

To enable the product’s import to India, patients need to provide:

  1. A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
  2. Recent medical history and test reports (preferably from the last three months), including those confirming disease. 
  3. Government-issued ID proof and proof of residence of the patient.
  4. Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Tukysa from the USA, Canada, Europe, or Australia, etc. 
With these steps, patients can import tucatinib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.


October 17, 2025
Anakinra-Blog-17-10-2025-1280x800.jpg

Kineret, also known by its generic name Anakinra, is a biologic prescription medicine that belongs to the class of interleukin-1 receptor antagonists (IL-1Ra), produced by recombinant DNA technology. It works by blocking the activity of interleukin-1 (IL-1), a protein involved in inflammation. By reducing IL-1 activity, it helps control symptoms and progression of several rare and severe inflammatory diseases.

Kineret is approved for treating:

  1. Rheumatoid Arthritis (RA) in adults who have not responded to one or more other treatments.
  2. Neonatal-Onset Multisystem Inflammatory Disease (NOMID): A rare form of Cryopyrin-Associated Periodic Syndromes (CAPS).
  3. Deficiency of Interleukin-1 Receptor Antagonist (DIRA): A life-threatening genetic condition

Adverse reactions can include infections in upper respiraotory tract, injection site reaction, worsening of rheumatoid arthritis,, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain in RA patients; injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis in NOMID patients; upper respiratory tract infections, rash, pyrexia, influenza like illness, and gastroenteritis in DIRA patients. Higher risk of adverse reactions and their severity in geriatric patients and those with renal impairment. Refer label for detailed drug information.  

Anakinra (Kineret) is a vital biologic therapy for patients with Rheumatoid Arthritis, NOMID, and DIRA, offering significant improvements in health outcomes and, in some cases, survival. While the Kineret price in India can vary, legal import channels ensure transparency and access to genuine medicine.

Pricing and availability: 

Anakinra is prescribed for patients requiring treatment of rheumatoid arthritis, NOMID and DIRA. However, ankainnra is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for anakinra is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. 

The price of anakinra (Kineret) in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy anakinra India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access

As Anakinra is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients to products like Kineret in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Anakinra or Kineret is supplied in 100 mg/0.67 mL prefilled syringes (packs of 28 injections),

Import process:

  1. Request submission for your medicine
    Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
  2. Submission of an application (Form 12A)
    Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
  3. Verification of documents
    We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
  4. Permission to import
    Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
  5. Sourcing the medicine
    Our sourcing team connects with authorized global suppliers to find the best anakinra price in India, confirm easy import of anakinra in India, and ensure authenticity before finalizing the offer.
  6. Delivery of the medicine
    After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require: 

To enable the product’s import to India, patients need to provide:

  1. A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
  2. Recent medical history and test reports (preferably from the last three months), including those confirming disease. 
  3. Government-issued ID proof and proof of residence of the patient.
  4. Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Kineret from the USA, Canada, Europe, or Australia, etc. 
With these steps, patients can import anakinra in India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.


October 15, 2025
Blinatumomab-Blincyto-1280x800.png

Blinatumomab belongs to the group of chemotherapeutic drugs “BiTES” or bispecific T-cell engagers.  Blinatumomab is particularly directed to CD19 on B cells and  CD3 on T-cells. This antibody based therapy is produced in CHO cell lines or Chinese hamster ovary cells. 

Blinatumomab engages and activates endogenous T-cells as it is  particularly directed to CD19 on benign and malignant B cells and  CD3in TCR complex  on T-cells. This allows formation of a synapse between the T-cell and the tumor cell, thus upregulating cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T-cells, ultimately resulting in lysis of CD19+ cells. 

Blinatumomab is indicated for the treatment of aadults and pediatric patients one month or older with the following: 

  1. CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% . 
  2. Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).
  3. CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. 

Some of the adverse reactions associated with blinatumomab use include cytokine release syndrome, neurological toxicities, including ICANS (immune effector cell-associated neurotoxicity syndrome), infections, tumor lysis syndrome, neutropenia and febrile neutropenia, effects on ability to drive and use machines, elevated liver enzymes, pancreatitis, leukoencephalopathy

Pricing and availability: 

Blincyto 38.5 mcg Injection in India is usually prescribed by hematologists and oncologists, especially for patients who are candidates for bone marrow transplant (BMT). However, Blincyto is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for blinatumomab is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. 

The price of Blincyto (blinatumomab) in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy blinatumomab in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access: 

As blinatumomab is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients in the import of blinatumomab India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Each Blincyto package contains:  One blinatumomab for injection 35 mcg single-dose vial and one IV Solution Stabilizer 10 mL single-dose glass vial.  It is administered as an intravenous injection and the dose is as follows: 

  1.  Day 1-28:
    • 28 mcg/day for weight > 45 kg 
    • 15 mcg/day for weight < 45 kg.
  2. Day 29-42:
    • 14-day treatment interval 

Import process:

  1. Request submission for your medicine
    Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
  2. Submission of an application (Form 12A)
    Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
  3. Verification of documents
    We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
  4. Permission to import
    Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
  5. Sourcing the medicine
    Our sourcing team connects with authorized global suppliers to find the best blincyto price in India, confirm easy import blinatumomab in India, and ensure authenticity before finalizing the offer.
  6. Delivery of the medicine
    After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require: 

To enable the product’s import to India, patients need to provide:

  1. A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
  2. Recent medical history and test reports (preferably from the last three months), including those confirming the disease. 
  3. Government-issued ID proof and proof of residence of the patient.
  4. Import permit if applicable.

The order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Blincyto from the USA, Canada, Europe, or Australia etc. 
With these steps, patients can import blinatumomab in India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing, and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before being delivered to patients.


October 13, 2025
Sacituzumab-Govitecan-1-1280x800.jpg

Trodelvy® (brand name by Gilead sciences)(sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate used to treat metastatic triple-negative and HR+/HER2- breast cancers in adults who have received prior therapies. It delivers SN-38, a topoisomerase-1 inhibitor, to Trop-2-expressing tumor cells, blocking DNA replication and causing cell death.

Mode of action of sacituzumab govitecan-hziy is mainly that it delivers SN-38, a topoisomerase-1 inhibitor, to Trop-2-expressing cancer cells. It treats adults with metastatic triple-negative breast cancer (TNBC) after two or more prior therapies, and HR+/HER2- metastatic breast cancer after endocrine and systemic therapies. It’s also used for locally advanced or metastatic urothelial cancer post-platinum and PD-1/PD-L1 inhibitor treatment. 

Neutropenia, diarrhea, hypersensitivity and infusion-related reactions, nausea and vomiting are the common side effects.  Trodelvy may have teratogenic effects and can cause embryo-fetal lethality when administered during pregnancy. 

Trodelvy promises to help in overall survival of metastatic cancer which is difficult to treat with other therapies, and being a targeted therapy, it allows precise delivery of drugs and an increased chances of survival with less or no progression. 

Pricing and Availability

The price of sacituzumab govitecan-hziy in India may vary depending on market dynamics, supplier availability, and regulatory updates. For the most accurate and updated sacituzumab govitecan-hziy pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy sacituzumab govitecan in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access

We assist patients and hospitals in legally importing for personal medical use and provide reliable access across major Indian cities. Sacituzumab govitecan-hziy is a prescription drug available as 180 mg lyophilized powder in single-dose vials for reconstitution, for injection. and requires a valid medical prescription from a qualified doctor. It can be imported under the Named Patient Supply (NPS) program, which allows patients to access unapproved or unavailable medicines in India for personal treatment use.

Access Process:

  1. Request submission for your medicine: Patients or caregivers can send a request for sacituzumab govitecan-hziy by sharing prescription details and treatment requirements.
  2. Submission of an application (Form 12A): Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
  3. Verification of documents: We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
  4. Permission to import: Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
  5. Sourcing the medicine: Our sourcing team connects with authorized global suppliers to find the best sacituzumab govitecan-hziy or trodelvy price in India, confirm easy access trodelvy in India, and ensure authenticity before finalizing the offer.
  6. Delivery of the medicine: After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of sacituzumab govitecan-hziy to the patient’s location in India.

Documents Require: 

To enable sacituzumab import to India, patients need to provide:

  1. A doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
  2. Recent medical history and test reports (preferably from the last three months).
  3. Government-issued ID proof and proof of residence of the patient.
  4. Import permit if applicable. 

The order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Trodelvy from the USA, Canada, Europe, or Australia, etc.  

With these steps, patients can import sacitizumab-govitecan India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.


October 10, 2025
Foscarnet-1280x800.jpg

Foscarnet is an antiviral drug primarily used to treat cytomegalovirus (CMV) associated retinitis in patients with AIDS and acyclovir-resistant herpes simplex virus (HSV) infections in immunocompromised individuals. It is especially essential when standard antiviral treatments such as acyclovir or ganciclovir fail due to viral resistance.

Foscarnet does not require activation by viral enzymes, unlike other antiviral agents. It acts by blocking the pyrophosphate-binding site of viral DNA polymerase, inhibiting viral DNA synthesis without affecting normal cellular DNA polymerases. This unique, non-nucleoside pyrophosphate analog mechanism gives Foscarnet potent activity against herpesviruses, including CMV, HSV, and varicella-zoster virus (off label treatment) and HIV.

Clinically, Foscarnet is FDA-approved for treating CMV retinitis in patients with AIDS who cannot tolerate or have failed ganciclovir therapy, and as a salvage therapy in resistant CMV infections and for mucocutaneous HSV infections unresponsive to acyclovir in immunocompromised patients.

Foscarnet’s key advantage lies in its distinct mechanism of action, making it effective against drug-resistant herpesvirus strains. This makes it the drug of choice for managing severe, resistant CMV and HSV infections in vulnerable, immunocompromised patients.

Access

We assist patients and hospitals in legally importing Foscranet for personal medical use and provide reliable access across major Indian cities.

Foscarnet is a prescription drug available as 250 mL glass bottles containing 6000 mg foscarnet sodium (24 mg/mL) for single use vial and requires a valid medical prescription from a qualified doctor. It can be imported under the Named Patient Supply (NPS) program, which allows patients to access unapproved or unavailable medicines in India for personal treatment use.

Access Process:

  1. Send a request for your medicine: Patients or caregivers can send a request for Foscarnet by sharing prescription details and treatment requirements.
  2. Submission of an application (Form 12A): Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
  3. Verification of documents: We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
  4. Permission to import: Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
  5. Sourcing the medicine: Our sourcing team connects with authorized global suppliers to find the best foscarnet price in India, confirm Foscarnet availability in India, and ensure authenticity before finalizing the offer.
  6. Delivery of the medicine: After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of Foscarnet to the patient’s location in India.

Documents Required:

To import Foscarnet into India, patients need to provide:

  • A doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
  • Recent medical history and test reports (preferably from the last three months).
  • Government-issued ID proof and proof of residence of the patient.

Pricing and Availability:

The price of Foscarnet in India may vary depending on market dynamics, supplier availability, and regulatory updates. For the most accurate and updated Foscarnet pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy foscarnet in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.


October 9, 2025
Mitotane-Lysodren-1280x800.jpg

LYSODREN or Mitotane is indicated in the treatment of inoperable, functional or nonfunctional adrenocortical carcinoma of both functional and nonfunctional types, as well as used as an off-label treatment for the management of Cushing’s syndrome. Mitotane inhibits cells of the adrenal cortex and their production of hormones and has been used for this purpose since 1959.
Mitotane is indicated for the treatment of inoperable, functional or nonfunctional adrenocortical carcinoma.

Access to Mitotane in India : 

We assist patients and hospitals in legally importing Mitotane (Lysodren) for personal medical use and provide reliable access across major Indian cities.

Mitotane is a prescription drug available in 500 mg tablets and requires a valid medical prescription from a qualified doctor. It can be imported under the Named Patient Supply (NPS) program, which allows patients to access unapproved or unavailable medicines in India for personal treatment use.

Access Process:

  1. Send a request for your medicine
    Patients or caregivers can send a request for Mitotane (Lysodren) by sharing prescription details and treatment requirements.
  2. Submission of an application (Form 12A)
    Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
  3. Verification of documents
    We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
  4. Permission to import
    Once approval is granted by the Drugs Controller General (India), the process of importing Mitotane begins as per the prescription.
  5. Sourcing the medicine
    Our sourcing team connects with authorized global suppliers to find the best mitotane price in India, confirm mitotane availability in India, and ensure authenticity before finalizing the offer.
  6. Delivery of the medicine
    After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of Mitotane (Lysodren) to the patient’s location in India.

Documents Require:

To import Mitotane (Lysodren) into India, patients need to provide:

  • A doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
  • Recent medical history and test reports (preferably from the last three months).
  • Government-issued ID proof and proof of residence of the patient.

Pricing and Availability

The price of Mitotane (Lysodren) in India may vary depending on market dynamics, supplier availability, and regulatory updates. For the most accurate and updated Mitotane pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy Mitotane in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.


October 6, 2025
Encorafenib-Braftovi-in-India-Pricing-Import-Steps-Access-Guide-1.png

BRAFTOVI (encorafenib) is a prescription medication used to treat certain cancers that have spread (metastasized), cannot be removed with surgery, and have specific mutations in the BRAF gene. It is used in the following ways:

  1. Melanoma and Non-Small Cell Lung Cancer (NSCLC): In combination with MEKTOVI (binimetinib), BRAFTOVI is used to treat adults with melanoma or NSCLC that has a BRAF mutation.
  2. Colorectal Cancer (CRC): In combination with cetuximab and mFOLFOX6 (a chemotherapy regimen including fluorouracil, leucovorin, and oxaliplatin) to treat colorectal cancer.

The approval for this combination was based on tumor response and the duration of that response. Ongoing studies are evaluating the clinical benefit of this regimen.
Encorafenib may also be used in combination with cetuximab alone for adults with colorectal cancer who have previously received treatment.
Important Note:
Encorafenib should not be used in people whose melanoma, colorectal cancer, or NSCLC has wild-type BRAF (no mutation). Your healthcare provider will perform a test to confirm if Encorafenib or the combination with binimetinib is appropriate for your condition.

BRAFTOVI helps improve tumor response and duration of benefit. When paired with binimetinib or cetuximab-based regimens, it offers powerful, personalized treatment designed to enhance anti-tumor response and extend control. It is not suitable for cancers without the BRAF mutation.

It is currently not known whether encorafenib or binimetinib is safe or effective in children.

Encorafenib is a BRAF kinase inhibitor targeting mutated BRAF – BRAF V600E, wild-type BRAF, and CRAF, inhibiting tumor growth via the suppression of RAF/MEK/ERK pathway. It also binds other kinases at clinically relevant levels. In combination with binimetinib or cetuximab, it showed enhanced anti-tumor effects and delayed resistance in BRAF-mutant models. Resistance in BRAF-mutant CRC due to EGFR activation can be overcome with EGFR-targeted combination therapy.

The drug is marketed globally by Pfizer Inc., and has received FDA approval for use in specific BRAF mutation associated cancers. While Braftovi is available in India, it is generally accessed via named-patient import programs, ensuring legal and safe delivery for patients who need it.

By partnering with licensed facilitators such as 24/7QualityMeds, patients can navigate the import process for Braftovi in India with confidence, ensuring safe access to this essential cancer treatment. For individuals with qualifying prescriptions, this pathway offers a vital bridge to advanced therapies that can significantly improve quality of life and treatment outcomes.

Pricing

The Braftovi price in India may vary based on factors such as dosage, duration of therapy, and sourcing channels as well as origin of import and manufacturer supply-chain costs. Patients seeking encorafenib in India are encouraged to request a quotation through authorized facilitators like 24/7QualityMeds, which helps ensure genuine supply and transparent pricing.

It is recommended that patients consult their oncologist for exact dosage requirements and obtain a valid prescription before proceeding with the purchase. Costs are finalized after verification of documentation and confirmation of availability through global suppliers.

Access Steps

We assist patients and hospitals in legally importing Braftovi (encorafenib) for medical use. We provide reliable access across major Indian cities. The following steps are required : 

  1. Request for medicine: Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
  2. Verification of documents: The prescription and related medical records are verified to confirm eligibility for importing the drug in small quantities for personal use.
  3. Permission to import: After approval from the Drugs Controller General (India), the process of importing the medicine begins as per the prescription.
  4. Sourcing the medicine: Our sourcing experts connect with global suppliers to find the best available price and confirm availability before finalizing the offer.
  5. Delivery of the medicine: Once approved, the our team arranges shipping and ensures timely and safe delivery of the medicine to the patient.

Documents required:

  1. A doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
  2. Medical history and test reports (preferably from the last three months).
  3. Government-issued identity proof and proof of residence of the patient.

These steps ensure that patients can import and buy encorafenib in India safely, legally, and with full regulatory compliance under the Named Patient Supply (NPS) program.


October 4, 2025
Tucatinib-Blog-04-10-2025-1280x800.jpg

Introduction

Tukysa (generic name: tucatinib) is a targeted cancer therapy used to treat HER2-positive breast cancer that is locally advanced or metastatic (spread to other parts of the body). It is especially indicated for patients whose cancer has progressed despite prior therapies. Tucatinib works by blocking the HER2 protein, which fuels the growth of cancer cells, thereby helping slow disease progression.

In addition to breast cancer, the U.S. FDA granted accelerated approval in January 2023 for tucatinib in combination with trastuzumab for the treatment of RAS wild-type HER2-positive metastatic colorectal cancer that has progressed after standard chemotherapy.

Tukysa is supplied as oral tablets and is a prescription-only medication, meaning it can only be dispensed with a valid doctor’s prescription. Patients in India who need to access this medicine can do so legally via named-patient import programs, supported by authorized facilitators.

Tucatinib (Tukysa) is an important therapy for patients with HER2-positive breast cancer and colorectal cancer, offering hope when other treatments have failed. While the tukysa price in India may vary depending on sourcing and logistics, patients can legally buy tucatinib in India through named-patient import programs with the right documentation.

For patients and doctors exploring tucatinib availability in India, working with authorized facilitators ensures: Genuine and reliable supply from international sources. 100% transparency in cost and process. Compliance with legal import requirements

Pricing

The Tukysa price in India varies depending on:

Dosage requirements and treatment duration.

The country of origin (USA, Canada, Europe, or Australia).

Import duties, handling, and logistics costs.

As the drug is not yet manufactured or widely marketed in India, the price can only be determined once sourcing and shipping details are finalized. Patients who want to buy tucatinib in India are advised to work with verified import facilitators who can provide transparent pricing, ensure authenticity, and guide them through the legal process.

Since Tukysa is often imported on a named-patient supply (NPS) basis, the costs may be higher than locally available alternatives, but this process guarantees genuine supply and compliance with Indian law. Patients are strongly advised against relying on unverified sources that may supply counterfeit or unsafe products.

Access Steps

Patients or hospitals seeking to import tucatinib in India must follow a regulated process to ensure the medicine is dispensed safely and legally.

  1. Required Documentation
    • A valid prescription from a qualified oncologist.
    • Patient’s diagnostic reports confirming HER2-positive breast cancer or other approved indications.
    • Government-issued ID proof of the patient.
    • An import permit (if required by Indian authorities).
  1. Application Process
    • The application is generally filed under Form 12A for personal use, along with the prescription and supporting medical documents. Import permits are issued in the patient’s name, ensuring the medicine is used only for the intended recipient.
  1. Order Confirmation
    • Orders are confirmed once all documents are received and verified. This ensures compliance with Indian drug regulations.
  1. Distribution Across India
    • Tukysa (tucatinib) can be made available in major cities including Delhi, Mumbai, Kolkata, Bangalore, Hyderabad, Chennai, Ahmedabad, Pune, Jaipur, Lucknow, Kochi, Chandigarh, and more. Delivery is handled only after verification of prescriptions to maintain patient safety

For patients seeking Tucatinib (Tukysa) in India, understanding how to access it safely and legally can feel stressful. Questions about availability, cost, and the proper process to obtain it are common, and having the right guidance makes the process much easier.Trusted platforms like 24/7QualityMeds provide step-by-step guidance to help patients understand the process, check costs, and access the medication safely. You can get personalized support by reaching out at +91 99679 79080. With the right guidance, patients can confidently explore legal options to obtain Tucatinib and continue their treatment journey.


October 3, 2025
Anakinra-Blog-03-10-2025-1280x800.jpg

Introduction

Kineret, also known by its generic name Anakinra, is a biologic prescription medicine that belongs to the class of interleukin-1 receptor antagonists (IL-1Ra). Supplied in 100 mg/0.67 mL prefilled syringes (packs of 28 injections), it works by blocking the activity of interleukin-1 (IL-1), a protein involved in inflammation. By reducing IL-1 activity, it helps control symptoms and progression of several rare and severe inflammatory diseases.

Kineret is approved for treating:

  • Rheumatoid Arthritis (RA): For adults with moderate to severe RA who have not responded to one or more other treatments.
  • Neonatal-Onset Multisystem Inflammatory Disease (NOMID): A rare form of Cryopyrin-Associated Periodic Syndromes (CAPS).
  • Deficiency of Interleukin-1 Receptor Antagonist (DIRA): A life-threatening genetic condition where the drug is essential to survival.

Patients with DIRA and NOMID often rely on Anakinra (Kineret) as a life-saving intervention. By reducing systemic inflammation, the drug improves quality of life, prevents complications, and supports healthy growth and development in children.

Anakinra (Kineret) is a vital biologic therapy for patients with Rheumatoid Arthritis, NOMID, and DIRA, offering significant improvements in health outcomes and, in some cases, survival. While the Kineret price in India can vary, legal import channels ensure transparency and access to genuine medicine.

Patients seeking to buy Anakinra in India, confirm the latest Kineret price India, or learn more about Anakinra availability in India can rely on authorized facilitators for safe and legal procurement. With the right documentation and compliance, Kineret can be accessed across India and other countries where it is not locally marketed.

Phone: [+919967979080]
Website: [24/7qualitymeds.com]

 With proper guidance and support, patients can access Kineret (Anakinra) safely, ensuring timely treatment for complex inflammatory conditions.

Pricing

The Kineret price in India can vary depending on several factors, including:

  • Pack size and dosage requirement.
  • Source of procurement (USA, Canada, or Europe).
  • Import duties, handling, and logistics costs.

Because of these variables, patients are encouraged to confirm the latest price of Anakinra in India through authorized import facilitators. Since Kineret is not always available in local pharmacies, the medicine is often sourced through legal named-patient import programs.

Indian Pharma Network (IPN) assists patients and hospitals in obtaining genuine Kineret at the lowest possible price while ensuring full compliance with Indian regulations. Patients from India as well as countries such as Bangladesh, Nepal, Sri Lanka, Afghanistan, Maldives, and Pakistan can rely on IPN for access to this therapy.

Access Steps

Patients looking to buy Anakinra in India or arrange for import of Kineret must follow specific legal steps to ensure compliance and safety.

  1. Documentation Requirements

    • A valid prescription from a qualified doctor.
    • Patient’s diagnostic reports confirming the medical condition.
    • Government-issued ID proof of the patient.
    • An import permit, if applicable.
  2. Order Confirmation
    The order is confirmed only after submission and verification of all required documents. This ensures that the medicine is dispensed legally and safely.
  3. Named-Patient Supply (NPS)
    Kineret is made available in India through the Named-Patient Supply program, which allows patients access to medicines not yet registered locally. This process ensures transparency and regulatory compliance.
  4. Distribution Across India and Globally
    Kineret can be delivered to patients, doctors, and hospitals in major Indian cities including Delhi, Mumbai, Bangalore, Kolkata, Hyderabad, Chennai, Ahmedabad, and Pune, as well as internationally. IPN sources Anakinra from verified suppliers in the USA, Canada, and Europe, ensuring authenticity and quality.
  5. Safety Assurance
    All prescriptions are checked by registered pharmacists, and shipments are dispatched only to the patient’s registered address, reducing the risk of counterfeit products. Patients are strongly advised not to purchase from unverified sources, which may supply unsafe or fake medicines.

Access to Anakinra (Kineret) in India is available through authorized import programs, ensuring patients receive genuine medicine safely and on time. For the latest Anakinra price in India, step-by-step import guidance, and reliable support, patients and caregivers can contact 247QualityMeds to secure treatment with confidence.